

Product Introduction

Atomoxetine HCI

Atomoxetine is a selective **norepinephrine (NE) transporter** inhibitor with K_I of 5 nM, with 15- and 290-fold lower affinity for human 5-HT and DA transporters. Phase 4.

Technical Data:

Molecular Weight (MW):	291.82	
Formula:	C ₁₇ H ₂₁ NO.HCl	
Solubility (25°C)	DMSO 58 mg/mL	N HCI
* <1 mg/ml means slightly	Water 2 mg/mL	
soluble or insoluble:	Ethanol 37 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder	
	6 months-80℃in DMSO	
CAS No.:	82248-59-7	

Biological Activity

Atomoxetine is a selective norepinephrine reuptake inhibitor with K_i of 5 nM, compared with 77 and 1451 nM for binding to serotonin and dopamine transporters. ^[1]

In microdialysis studies, atomoxetine increases extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but does not alter 5-HT_{EX} levels. Atomoxetine also increases DA_{EX} concentrations in PFC 3-fold, but does not alter DA_{EX} in striatum or nucleus accumbens. Atomoxetine increases Fos by 3.7-fold in PFC, but not in the striatum or nucleus accumbens. $^{[1]}$ Atomoxetine selectively inhibits the presynaptic uptake of

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

norepinephrine in adrenergic neurons in animals, and has activity in animal models of depression. [2][3]

References

- [1] Bymaster FP, et al. Neuropsychopharmacology, 2002, 27(5), 699-711.
- [2] Zerbe RL, et al. J Pharmacol Exp Ther, 1985, 232(1), 139-143.
- [3] Wong DT, et al. J Pharmacol Exp Ther, 1982, 222(1), 61-65.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

